Steatohepatitis

Treatment with efruxifermin resulted in significant improvement in fibrosis at week 24 in patients with metabolic dysfunction-associated steatohepatitis, which was “sustained and expanded through week 96,” according to late-breaking data.

Survodutide was superior to placebo and significantly improved markers of metabolic dysfunction-associated steatohepatitis without worsening of fibrosis, according to data presented at EASL Congress.

Denifanstat, a fatty acid synthase inhibitor, outperformed placebo in metabolic dysfunction-associated steatohepatitis resolution without worsening of fibrosis and fibrosis improvement, according to data presented at EASL Congress.

WASHINGTON — Researchers have determined that several noninvasive tests could help identify candidates for treatment with Rezdiffra, as well as predict response, in metabolic dysfunction-associated steatohepatitis.

In a Healio video exclusive, Edward V. Loftus Jr., MD, urged gastroenterologists to familiarize themselves with a “four-pronged approach to liver disease” ahead of the critical shortage of U.S. hepatologists expected by 2033.

In a Healio video exclusive, Edward V. Loftus Jr., MD, highlighted how rebranding nonalcoholic fatty liver disease as metabolic dysfunction-associated steatotic liver disease offers a “positive diagnosis” without the associated stigma.

BOSTON — Pegozafermin improved fibrosis and other key noninvasive tests at 24 weeks in patients with metabolic dysfunction-associated steatohepatitis-related cirrhosis, according to data presented at The Liver Meeting.

BOSTON — Hispanic and Asian patients with metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma were less likely to undergo liver transplantation compared with other races and ethnicities, data showed.

VANCOUVER, British Columbia — Insulin resistance, HbA1c and waist circumference represent independent risk factors for metabolic dysfunction-associated steatotic liver disease among lean patients, according to data presented here.